JNJ

Johnson & Johnson demonstrates a bullish medium-term outlook as technical indicators suggest consolidation with potential for upside breakout. The convergence of 20 and 50-day SMAs near 225.70 indicates a transition phase. With an attractive PEG ratio of 0.50 and strong dividend support, the stock offers value for medium-term investors. Price target of $232 represents 3.4% upside with moderate-to-good confidence, contingent on MACD reversal confirmation.

• SMA 20 and SMA 50 converging near 225.70, suggesting consolidation phase
• Fundamental metrics show attractive valuation with PEG ratio of 0.50
• Strong dividend history supports medium-term holding thesis
• Healthcare sector positioning remains favorable for defensive investors

• MACD still negative, though histogram narrowing suggests potential reversal
• Debt-to-equity ratio of 1.47 indicates moderate leverage
• Earnings growth of 1.5% is modest relative to market expectations
• Sector rotation risk if growth stocks outperform

Actionable Items

• Monitor for MACD crossover above signal line as bullish confirmation
• Watch for break above 230 resistance with volume confirmation
• Consider accumulating on dips to 220 support level
• Track quarterly earnings for guidance updates

News Sentiment